The immunopathogenesis of chronic and relapsing autoimmune uveitis – Lessons from experimental rat models

Diedrichs-Möhring, Maria; Kaufmann, Ulrike; Wildner, Gerhild

doi:10.1016/j.preteyeres.2018.02.003

Cited by 44 publications

(37 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Retinal antigen-specific T cells activated in peripheral lymph nodes or spleens after immunization with interphotoreceptor retinoid-binding protein (IRBP) (Broderick et al, 2000;Dick, 2000;Ruhrmann et al, 2018) infiltrate into the retina (Li et al, 2019). Subsequent infiltration of non-specific T cells, macrophages and neutrophils interacting with local parenchymal cells causes inflammatory cascades leading to photoreceptor cell and retina damage (Diedrichs-Mohring et al, 2018;Edling et al, 2011). The subsets of T helper (Th) cells, particularly Th1 cells producing IFN-γ and Th17 cells producing IL-17A, play a pathogenic role in EAU (Amadi-Obi et al, 2007;Caspi, 2010;Shi et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Matairesinol ameliorates experimental autoimmune uveitis by suppression of IRBP-specific Th17 cells

Gao

Yang

et al. 2020

Journal of Neuroimmunology

View full text Add to dashboard Cite

We investigated the effects of matairesinol (MAT) in the experimental autoimmune uveitis (EAU), a classical animal model of uveitis. We found that treatment with MAT could alleviate intraocular inflammation of EAU. Notably, Th17 cells in eyes of EAU mice could be predominantly restrained by MAT. Furthermore, MAT could inhibit Th17 differentiation in vitro. In addition, MAT inhibited the signaling of MAPK and ROR-γt, a pivotal transcription factor for Th17 cell differentiation in vitro and in vivo. Taken together, these results suggested that MAT had immune-suppressive effects on autoimmune inflammation through Th17 cells. 2. Materials and methods 2.1. Mice All procedures involving mice were approved by the Laboratory Animal Care and

show abstract

Section: Introductionmentioning

confidence: 99%

Matairesinol ameliorates experimental autoimmune uveitis by suppression of IRBP-specific Th17 cells

Gao

Yang

et al. 2020

Journal of Neuroimmunology

View full text Add to dashboard Cite

show abstract

“…Experimental autoimmune uveitis (EAU) is an animal disease model of a T cell-mediated autoimmune disease that mimics many of the pathological features of human uveitis (45,46). EAU is induced by injecting animals with purified retinal antigens such as S-Ag, a fragment (residues 1-20, GPTHLFQPSLVLDMAKVLLD) of the human interphotoreceptor retinoid-binding protein (hIRBP); rhodopsin (or opsin); phosducin, or recoverin.…”

Section: Experimental Autoimmune Uveitismentioning

confidence: 99%

“…Many studies have demonstrated that monocytes-macrophages have a role in the development of EAU ( 58 ). Activated bone marrow–derived macrophages are required during the effector phase of EAU ( 45 ). However, in addition to their proinflammatory function, macrophages have suppressive effects on ocular inflammation, especially in the chronic phase.…”

Section: Non-infectious Uveitis (Niu)mentioning

confidence: 99%

New Insights Into Immunological Therapy for Retinal Disorders

et al. 2020

View full text Add to dashboard Cite

In the twentieth century, a conspicuous lack of effective treatment strategies existed for managing several retinal disorders, including age-related macular degeneration; diabetic retinopathy (DR); retinopathy of prematurity (ROP); retinitis pigmentosa (RP); uveitis, including Behçet's disease; and vitreoretinal lymphoma (VRL). However, in the first decade of this century, advances in biomedicine have provided new treatment strategies in the field of ophthalmology, particularly biologics that target vascular endothelial growth factor or tumor necrosis factor (TNF)-α. Furthermore, clinical trials on gene therapy specifically for patients with autosomal recessive or X-linked RP have commenced. The overall survival rates of patients with VRL have improved, owing to earlier diagnoses and better treatment strategies. However, some unresolved problems remain such as primary or secondary non-response to biologics or chemotherapy, and the lack of adequate strategies for treating most RP patients. In this review, we provide an overview of the immunological mechanisms of the eye under normal conditions and in several retinal disorders, including uveitis, DR, ROP, RP, and VRL. In addition, we discuss recent studies that describe the inflammatory responses that occur during the course of these retinal disorders to provide new insights into their diagnosis and treatment.

show abstract

“…MN-4是一株识别CD146的D4结构域的抗体, 不受甲醛固定影响, 广泛用于各类组织的石蜡切片检测中 [377] , 还可阻断CD146在抑制中间滋养层细胞向子宫肌层迁移方面的功能 [394] ; ME-9F1是常用的商品化用于流式检测等抗体, 由Klugewitz团队 [379] 在2008年首次报道, 特异识别鼠内皮细胞上CD146, 却不影响内表 4 CD146抗体无其他抗体 A32 [5] , MN-4 [377] , MUCBA18.1-18.5 [2] , M18/4G5 [378] , ME-9F1 [379] , OI-3 [380] , WM85/CC9/EB4 [166] , Shih IM-pAb [381] , IgY-pAb [382] , Antisera to shCD146/lgCD146 [383] , Gicerin [15] m146-pAb [384] , sc-Fv-B6-11 [385] , sc-Fv-M1 [295] , sc-Fv-IR94 [386] 皮的功能, 曾被报道在肝癌成像和治疗方面具有潜能 [395] ; OI-3是一株特异识别人骨肉瘤的鼠源单克隆抗体, 被进一步改造成人鼠嵌合抗体后, 耦连核素用于靶向治疗研究 [380] ; 为了研究骨髓基质细胞对造血功能的调控, Bradstock团队 [166] 制备了WM85, CC9和EB4等单…”

Section: 抗体、纳米抗体、单链抗体其中单克隆抗体包括unclassified